Abstract
The antibiotics start-up Entasis Therapeutics has raised $50 million in its second round of financing. Entasis was spun off from AstraZeneca in early 2015 after the big pharma firm failed to find a buyer for the unit. AstraZeneca initially committed up to $40 million to the new company; this next funding round, from outside firms, will help support Entasis’s most advanced drug candidate, ETX0914, a gyrase inhibitor in Phase II studies to treat gonorrhea.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
